Letters Cancer drugs, survival, and ethics

Something must be done—but chemotherapy isn’t the only option

BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6455 (Published 05 December 2016) Cite this as: BMJ 2016;355:i6455
  1. Caroline Mawer, self employed
  1. London, UK
  1. caroline.mawer{at}gmail.com

Wise challenges the usefulness of chemotherapy drugs in patients with metastatic cancer,1 and Hewlett “gets it” that a survival benefit of only a few months may not be fundable from a health economist’s point of view.2 Understandably, though, Hewlett highlights the potential personal benefit of chemotherapy.

So …

View Full Text

Sign in

Log in through your institution